Nanosphere (Nasdaq: NSPH) reported a loss for the fourth quarter and cut its projected enteric pathogens panels placements in the first quarter.

Encana (NYSE: ECA) posted a fourth quarter loss and said that its search for a new chief executive may take as long as three to six months.

The Food and Drug Administration expanded an import ban to include three Hospira (NYSE: HSP) intravenous pumps manufactured in Costa Rica.

In the broad market, declining issues were on par with advancers on the NYSE while advancers edged out decliners by a margin of more than 10 to 9 on Nasdaq. The broader S&P 500 index added a point to 1521.